6 results on '"Youssef Daali"'
Search Results
2. Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review
- Author
-
Youssef Daali, Yassine Bouatou, Pierre Fontana, Jules Alexandre Desmeules, and Caroline Flora Samer
- Subjects
Ticagrelor ,medicine.medical_specialty ,Adenosine ,Ticlopidine ,Prasugrel ,medicine.medical_treatment ,Clinical Biochemistry ,Population ,Pharmacology ,End stage renal disease ,Internal medicine ,medicine ,Animals ,Humans ,Risk factor ,education ,Dialysis ,ddc:616 ,ddc:615 ,education.field_of_study ,ddc:617 ,business.industry ,medicine.disease ,Clopidogrel ,Cardiovascular Diseases ,Purinergic P2Y Receptor Antagonists ,Kidney Failure, Chronic ,business ,Prasugrel Hydrochloride ,Platelet Aggregation Inhibitors ,medicine.drug ,Kidney disease - Abstract
Chronic kidney disease has been identified as an independent cardiovascular risk factor. The morbidity and mortality due to cardiovascular disease are higher among chronic kidney disease patients when compared with patients with normal kidney function. Although P2Y12 inhibitors (eg. clopidogrel) are associated with increased survival rates after a myocardial infarction, most of the clinical trials excluded End-Stage Renal Disease (ESRD) patients. Besides, non-responders to P2Y12 inhibitors have been identified as at risk of cardiovascular adverse events and non-responder prevalence is higher among ESRD than in any other population. Recent data questioned the benefits from P2Y12 inhibitors among chronic kidney disease patients. This systematic review aimed to describe pharmacokinetics (PK) and pharmacodynamics (PD) evidence data among 3 widely prescribed P2Y12 inhibitors. Clopidogrel and prasugrel are bioactivated by the cytochromes P450 (CYP) while ticagrelor is already active. PD data used different assays among which the VerifyNow® which showed intravariability before and after dialysis. The potential explanation of modulated PK/PD parameters among ESRD patients will be addressed. Absorption as well as metabolism is diminished in ESRD patients. It could potentially lead to absence of clopidogrel or prasugrel bioactivation or ticagrelor accumulation. Evidence-based recommendation regarding the best option for antiaggregation secondary to percutaneous intervention in this high risk population is still lacking.
- Published
- 2015
3. Markers of Individual Drug Metabolism: Towards the Development of a Personalized Antidepressant Prescription
- Author
-
Frank Bellivier, Jean-Michel Aubry, Célia Lloret-Linares, Jules Alexandre Desmeules, Kyle Heron, Patricia Berney, Marie Besson, Youssef Daali, and Emmanuel Haffen
- Subjects
Drug ,medicine.medical_specialty ,media_common.quotation_subject ,Clinical Biochemistry ,Drug intolerance ,Pharmacology ,ddc:616.89 ,Medicine ,Humans ,Medical prescription ,Precision Medicine ,Intensive care medicine ,media_common ,chemistry.chemical_classification ,ddc:615 ,ddc:617 ,business.industry ,Mechanism (biology) ,Genetic Variation ,Antidepressive Agents ,Phenotype ,Tolerability ,chemistry ,Antidepressant ,Drug Monitoring ,business ,Drug metabolism ,Biomarkers ,Tricyclic - Abstract
The development of a personalized psychopharmacotherapy could potentially reduce treatment failure associated with drug intolerance or resistance, and therefore the burden and costs of affective disorders. An important challenge in realising this potential will be to identify suitable markers of an individual's metabolic response to specific pharmaceuticals. In the absence of suitable markers related directly to drug mechanism, the drug-metabolizing enzymes and transporters have emerged as major determinants of variability in drug metabolism and response. In keeping with this emergent general pharmacological trend, numerous studies concerning the relationship between antidepressants, their metabolism, transport, pharmacokinetic properties, efficacy and tolerability have now been published. These studies are reviewed in this article. The studies considered here frequently support a link between enzyme/transporter activity and/or the pharmacokinetic parameters of antidepressants. However, the majority of studies explored the variability of tricyclic antidepressants, which are less often prescribed today. Furthermore only a few studies have been conducted in naturalistic clinical conditions, seeking to determine whether the systematic assessment of the variability may improve the management of 'real-world' patients. Nonetheless recent studies have yielded promising results regarding the potential benefits of determining drug metabolism variability which might encourage additional large-scale prospective systematic studies be set up to assess the relevance of this approach in everyday practice.
- Published
- 2014
4. Transcriptional regulation of CYP2C19 and its role in altered enzyme activity
- Author
-
Chakradhara Rao S. Uppugunduri, Youssef Daali, Jules Alexandre Desmeules, Maja Krajinovic, Pierre Dayer, and Marc Ansari
- Subjects
Pharmacology ,Regulation of gene expression ,Genetics ,ddc:618 ,ddc:617 ,Transcription, Genetic ,Clinical Biochemistry ,Response element ,Genetic Variation ,Promoter ,Biology ,Gene Expression Regulation, Enzymologic ,Cytochrome P-450 CYP2C19 ,Pharmaceutical Preparations ,Transcription (biology) ,Transcriptional regulation ,Humans ,Aryl Hydrocarbon Hydroxylases ,Allele ,Transcription factor ,Gene - Abstract
Cytochrome P450 2C19 (CYP2C19) is involved in the metabolism of several drugs that are currently in clinical use. The gene encoding CYP2C19 is polymorphic with the existence of different alleles resulting in altered enzyme activity. In addition, CYP2C19 activity is also dependent on its basal expression levels determined by the transcriptional regulation. Genetic variations located in the CYP2C19 promoter region may alter the interaction of promoter with transcription factors causing variable transcription. Genetic variants may also influence the induction, inhibition of CYP2C19 and may as well affect drug-drug interactions involving CYP2C19 substrates. The role of various transcription factors and genetic variants in the promoter region of CYP2C19 regulating its expression are discussed in this review. Furthermore, induction and inhibition of CYP2C19 by various drugs in clinically meaningful drug interactions are also discussed.
- Published
- 2012
5. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability
- Author
-
Virginie Ancrenaz, Marie Besson, Jules Alexandre Desmeules, Pierre Fontana, Caroline Flora Samer, Pierre Dayer, and Youssef Daali
- Subjects
Acute coronary syndrome ,Prasugrel ,Ticlopidine ,Thienopyridine ,Clinical Biochemistry ,Biological Availability ,CYP2C19 ,Thiophenes ,Pharmacology ,Piperazines ,P2Y12 ,Cytochrome P-450 Enzyme System ,Medicine ,Animals ,Humans ,Drug Interactions ,cardiovascular diseases ,Aspirin ,Prasugrel Hydrochloride ,Polymorphism, Genetic ,business.industry ,Clopidogrel ,medicine.disease ,Purinergic P2Y Receptor Antagonists ,business ,Platelet Aggregation Inhibitors ,circulatory and respiratory physiology ,medicine.drug - Abstract
Thienopyridine antiaggregating platelet agents (clopidogrel and prasugrel) act as irreversible P2Y12 receptor inhibitors. They are used with aspirin to prevent thrombotic complications after an acute coronary syndrome or percutaneous coronary intervention. A large interindividual variability in response to clopidogrel and to a lesser extent to prasugrel is observed and may be related to their metabolism. Clopidogrel and prasugrel are indeed prodrugs converted into their respective active metabolites by several cytochromes P450 (CYPs). Besides clopidogrel inactivation (85%) by esterases to the carboxylic acid, clopidogrel is metabolized by CYPs to 2-oxo-clopidogrel (15%) and further metabolized to an unstable but potent platelet-aggregating inhibitor. Prasugrel is more potent than clopidogrel with a better bioavailability and lower pharmacodynamic variability. Prasugrel is completely converted by esterases to an intermediate oxo-metabolite (R-95913) further bioactivated by CYPs. Numerous clinical studies have shown the influence of CYP2C19 polymorphism on clopidogrel antiplatelet activity. Moreover, unwanted drug-drug pharmacokinetic interactions influencing CYP2C19 activity and clopidogrel bioactivation such as with proton pump inhibitors remain a matter of intense controversy. Several studies have also demonstrated that CYP3A4/5 and CYP1A2 are important in clopidogrel bioactivation and should also be considered as potential targets for unwanted drug-drug interactions. Prasugrel bioactivation is mainly related to CYP3A4 and 2B6 activity and therefore the question of the effect of drug-drug interaction on its activity is open. The purpose of this review is to critically examine the current literature evaluating the influence of genetic and environmental factors such as unwanted drug-drug interaction affecting clopidogrel and prasugrel antiplatelet activity.
- Published
- 2010
6. Lack of interaction of the NMDA receptor antagonists dextromethorphan and dextrorphan with P-glycoprotein
- Author
-
Pierre Dayer, Mouna Kanaan, Youssef Daali, and Jules Alexandre Desmeules
- Subjects
Metabolite ,Dextromethorphan/pharmacokinetics ,Clinical Biochemistry ,Pharmacology ,Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors ,Dextromethorphan ,Receptors, N-Methyl-D-Aspartate ,chemistry.chemical_compound ,P-Glycoprotein/physiology ,Dextrorphan ,medicine ,Electric Impedance ,Humans ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,Receptor ,Excitatory Amino Acid Antagonists/pharmacokinetics ,P-glycoprotein ,ddc:617 ,biology ,Chemistry ,Biological Transport ,Caco-2 ,Blood-Brain Barrier ,biology.protein ,NMDA receptor ,Efflux ,Dextrorphan/pharmacokinetics ,Caco-2 Cells ,Excitatory Amino Acid Antagonists ,medicine.drug - Abstract
The anti-N-methyl-D-aspartate (NMDA) effect of dextromethorphan (DEM) seems to be mainly related to the unchanged drug rather than to its more potent metabolite dextrorphan (DOR). The aim of our study was to assess the involvement of P-glycoprotein (P-gp) and pH conditions in the transmembranal transport of these two NMDA antagonists, using a human in vitro Caco-2 cell monolayer model. Transmission electron microscopy, transepithelial electrical resistance, [(3)H]-mannitol permeability, Western blot analysis and the bidirectional transport of the positive controls, rhodamine and digoxine were used to confirm model's integrity and validity. The bidirectional transport of DEM and DOR (1 to 100microM) across the monolayers was investigated in the presence and absence of the P-gp inhibitor cyclosporine A (10microM) at two pH conditions (pH 6.8/7.7-pH 7.4/7.4) and assessed with the specific and more potent P-gp inhibitor GF120918 (4microM). Analytical quantification was achieved using high performance liquid chromatography. At a pH gradient, DEM and DOR were subject to a significant active efflux transport (Papp(B-A) > 2-3x Papp(A-B); p
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.